The online version of this article (doi:10.1186/s12916-017-0817-5) contains supplementary material, which is available to authorized users.
TEX101 is a cell membrane protein exclusively expressed by testicular germ cells and shed into seminal plasma. We previously verified human TEX101 as a biomarker for the differential diagnosis of azoospermia, and developed a first-of-its-kind TEX101 ELISA. To demonstrate the clinical utility of TEX101, in this work we aimed at evaluating ELISA performance in a large population of fertile, subfertile, and infertile men.
Mass spectrometry, size-exclusion chromatography, ultracentrifugation, and immunohistochemistry were used to characterize TEX101 protein as an analyte in seminal plasma. Using the optimized protocol for seminal plasma pretreatment, TEX101 was measured by ELISA in 805 seminal plasma samples.
We demonstrated that TEX101 was present in seminal plasma mostly in a free soluble form and that its small fraction was associated with seminal microvesicles. TEX101 median values were estimated in healthy, fertile pre-vasectomy men (5436 ng/mL, N = 64) and in patients with unexplained infertility (4967 ng/mL, N = 277), oligospermia (450 ng/mL, N = 270), and azoospermia (0.5 ng/mL, N = 137). Fertile post-vasectomy men (N = 57) and patients with Sertoli cell-only syndrome (N = 13) and obstructive azoospermia (N = 36) had undetectable levels of TEX101 (≤0.5 ng/mL). A cut-off value of 0.9 ng/mL provided 100% sensitivity at 100% specificity for distinguishing pre- and post-vasectomy men. The combination of a concentration of TEX101 > 0.9 ng/mL and epididymis-specific protein ECM1 > 2.3 μg/mL provided 81% sensitivity at 100% specificity for differentiating between non-obstructive and obstructive azoospermia, thus eliminating the majority of diagnostic testicular biopsies. In addition, a cut-off value of ≥0.6 ng/mL provided 73% sensitivity at 64% specificity for predicting sperm or spermatid retrieval in patients with non-obstructive azoospermia.
We demonstrated the clinical utility of TEX101 ELISA as a test to evaluate vasectomy success, to stratify azoospermia forms, and to better select patients for sperm retrieval.
Additional file 1: Table S1. Parameters of SRM assay of TEX101 protein. (PDF 10.3 kb)12916_2017_817_MOESM1_ESM.pdf
Additional file 2: Table S2. Column statistics for TEX101 analysis in SP samples (N = 821) by ELISA using GndCl-based treatment protocol. (PDF 9.8 kb)12916_2017_817_MOESM2_ESM.pdf
Additional file 3: Figure S1. TEX101 levels measured in SP samples (N = 821) by ELISA using GndCl-based protocol. (PDF 25.4 kb)12916_2017_817_MOESM3_ESM.pdf
Additional file 4: Table S3. Diagnosis, sperm count, and TEX101 levels in SP of 17 infertile men with high sperm count. (PDF 75.7 kb)12916_2017_817_MOESM4_ESM.pdf
Additional file 5: Figure S2. Quantification of total and intracellular TEX101 in pooled SP samples by SRM assays. (PDF 21.4 kb)12916_2017_817_MOESM5_ESM.pdf
Additional file 6: Figure S3. Amount of TEX101 per microgram of digested total protein in different SP pools and their respective vesicle-free and vesicles fractions, as measured by SRM. (PDF 72.3 kb)12916_2017_817_MOESM6_ESM.pdf
Additional file 7: Figure S4. Relative amounts of TEX101 captured from SP pools by commercial (mPoly) or in-house-generated (23-ED-616.8) antibodies, as measured by SRM. (PDF 22.2 kb)12916_2017_817_MOESM7_ESM.pdf
Additional file 8: Figure S5. TEX101 stability in the whole semen. (PDF 135 kb)12916_2017_817_MOESM8_ESM.pdf
Additional file 9: Table S4. Column statistics for TEX101 analysis in seminal plasma samples (N = 805) using DOC-based protocol. (PDF 9.7 kb)12916_2017_817_MOESM9_ESM.pdf
Additional file 10: Figure S6. Correlation between sperm count and TEX101 levels in SP. (PDF 18.5 kb)12916_2017_817_MOESM10_ESM.pdf
Additional file 11: Table S5. The list of Standards for Reporting of Diagnostic Accuracy Studies (STARD2015) recommendations followed in the present work. (PDF 16.4 kb)12916_2017_817_MOESM11_ESM.pdf
Male Infertility Best Practice Policy Committee of the American Urological Association, Practice Committee of the American Society for Reproductive Medicine. Report on evaluation of the azoospermic male. Fertil Steril. 2006;86:S210–15.
Jarow JP, Espeland MA, Lipshultz LI. Evaluation of the azoospermic patient. J Urol. 1989;142:62–5. PubMed
Drabovich AP, Pavlou MP, Batruch I, Diamandis EP. Proteomic and mass spectrometry technologies for biomarker discovery. In: Issaq HJ, Veenstra TD, editors. Proteomic and metabolomic approaches to biomarker discovery. Waltham: Academic Press (Elsevier); 2013. p. 17–37. CrossRef
World Health Organization. WHO laboratory manual for the examination 62 and processing of human semen. 5th ed. Geneva: World Health Organization; 2010.
Martinez-Morillo E, Nielsen HM, Batruch I, Drabovich AP, Begcevic I, Lopez MF, et al. Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. J Proteome Res. 2014;13:1077–87. CrossRefPubMed
Drabovich AP, Martinez-Morillo E, Diamandis EP. Toward an integrated pipeline for protein biomarker development. Biochim Biophys Acta. 1854;2015:677–86.
Freour T, Com E, Barriere P, Bouchot O, Jean M, Masson D, et al. Comparative proteomic analysis coupled with conventional protein assay as a strategy to identify predictors of successful testicular sperm extraction in patients with non-obstructive azoospermia. Andrology. 2013;1:414–20. CrossRefPubMed
- Preclinical evaluation of a TEX101 protein ELISA test for the differential diagnosis of male infertility
Theano D. Karakosta
Eleftherios P. Diamandis
Andrei P. Drabovich
- BioMed Central
Neu im Fachgebiet Allgemeinmedizin
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II